Integra cuts 2026 outlook as flood recovery extends into next year

Integra LifeSciences lowered its 2026 outlook on October 2, as July flooding at its Cincinnati facility and revised assumptions for the wider business weighed on its forecast.

Annual revenue guidance is now $1.634 billion–$1.654 billion, versus $1.654 billion–$1.695 billion previously. Adjusted diluted earnings guidance falls to $2.30–$2.40 a share from $2.40–$2.50.

Calculated from those ranges, the revenue midpoint declines by $30.5 million, or about 1.8%, to $1.644 billion. That comparison measures the change in management's forecast; it is not a reported revenue decline or a comparison with analysts' estimates.

Recovery and results are still estimates

Integra estimates the disruption reduced third-quarter sales by roughly $7 million and expects a $15 million–$20 million fourth-quarter impact. Full manufacturing is expected to resume in the second quarter of 2027. Insurance recoveries are expected to offset much of the earnings impact, with claims still being assessed.

Preliminary third-quarter results include unaudited revenue of $410 million–$412 million, with adjusted diluted earnings of $0.55–$0.59 a share. Closing procedures remain incomplete. The company still projects annual operating cash flow of $190 million–$200 million.

A separate refinancing proposal

In another October 2 announcement, Integra launched a proposed $600 million, seven-year senior secured Term Loan B. It intends to combine the proceeds with other financing to refinance existing debt and cover fees and expenses.

Chief financial officer Lea Knight said the transaction is intended to extend debt maturities and preserve financial flexibility. The company cautioned that completion, final size, terms and pricing remain uncertain and subject to market and other customary conditions.

The distinction matters: a proposed refinancing is neither completed funding nor evidence that the factory's production shortfall has been resolved. Without final pricing and the full refinancing structure, readers cannot calculate the change in borrowing costs or assume that the announced loan amount represents additional operating cash.

For investors, the next useful checks are final quarterly results, the pace of manufacturing restoration, documented insurance recoveries and the financing's completed terms. Those are separate tests of operating recovery and balance-sheet flexibility, rather than interchangeable signs of progress.